Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lisa Raatz"'
Autor:
Jialei Sun, Chenhao Zhou, Yue Zhao, Xiaofei Zhang, Wanyong Chen, Qiang Zhou, Bo Hu, Dongmei Gao, Lisa Raatz, Zhefang Wang, Peter J. Nelson, Yuchao Jiang, Ning Ren, Christiane J. Bruns, Haijun Zhou
Publikováno v:
Redox Biology, Vol 41, Iss , Pp 101942- (2021)
Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 (QSOX1) acting as a cellular pro-oxidant, specifically in
Externí odkaz:
https://doaj.org/article/27aec234849244f1a00bdde094614739
Publikováno v:
Journal of Visualized Experiments.
The lack of suitable translational research models reflecting primary disease to explore tumorigenesis and therapeutic strategies is a major obstacle in esophageal adenocarcinoma (EAC). Patient-derived organoids (PDOs) have recently emerged as a rema
Autor:
Xiao-Fei Zhang, Yuchao Jiang, Hai-Jun Zhou, Qiang Zhou, Christiane J. Bruns, Peter J. Nelson, Zhefang Wang, Chenhao Zhou, Yue Zhao, Lisa Raatz, Dong-Mei Gao, Ning Ren, Jialei Sun, Wanyong Chen, Bo Hu
Publikováno v:
Redox Biology
Redox Biology, Vol 41, Iss, Pp 101942-(2021)
Redox Biology, Vol 41, Iss, Pp 101942-(2021)
Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 (QSOX1) acting as a cellular pro-oxidant, specifically in